Has John Marks, MD received payments from drug or device companies?

Yes. Drug and device makers reported $476,713 in general payments to John Marks, MD across 239 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Marks, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Marks, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Marks, MD

Colon & Rectal Surgery · Wynnewood, PANPI 1346212594

Payments from drug & device makers

$476,713in general payments, 2019–2025

Across 239 payments — averaging $1994.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Olympus America Inc.$322K
Intuitive Surgical$44K
Vascular Technology, Inc.$35K
Stryker$30K
Arthrex$24K
Medtronic$14K
plus $8K from 48 others

What the payments were for

Consulting fees$84,16554%
Speaking & faculty fees$43,65028%
Travel & lodging$9,4216%
Food & beverage$9,3046%
Education$8,0005%
Gifts$240%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Olympus America Inc.	3	$322,166
Intuitive Surgical	65	$44,317
Vascular Technology, Inc.	3	$35,000
Stryker	20	$29,760
Arthrex	15	$23,517
Medtronic	24	$14,241
Covidien LP	7	$2,651
Applied Medical Resources Corporation	2	$1,375
Virtual Incision Corporation	5	$526
Johnson & Johnson(2 entities)	6	$509
Baxter Healthcare	6	$264
W. L. Gore & Associates, Inc.	2	$256
Braintree Laboratories, Inc.	11	$184
TELA Bio, Inc.	1	$173
Davol Inc.	2	$164
Takeda Pharmaceuticals U.S.A., Inc.	6	$131
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	6	$123
Caris MPI, Inc.	4	$121
Conmed Corporation	2	$113
Trevena, Inc.	5	$96
Activ Surgical, Inc.	1	$96
Acelrx Pharmaceuticals, Inc.	1	$68
Boston Scientific	2	$63
Teleflex LLC	2	$59
Merck	3	$46
Incyte Corporation	2	$45
Convatec Inc.	2	$43
Genentech USA, Inc.	2	$37
Dentsply IH AB	1	$37
Alfasigma USA, Inc.	2	$37
Mauna Kea Technologies, Inc.	1	$36
Solventum Corporation	1	$34
Aroa Biosurgery Incorporated	1	$27
Smith+Nephew	2	$26
Avanos Medical	1	$25
THD America, Inc.	2	$24
La Jolla Pharmaceutical Company	1	$24
Coloplast	1	$22
Vertex	1	$22
Pfizer	1	$20
Shire North American Group Inc	1	$20
Myriad Genetic Laboratories, Inc.	1	$19
Getinge USA Sales, LLC	1	$19
Acell, Inc.	1	$18
Innocoll Pharmaceuticals Limited	1	$17
Bayer	1	$17
AbbVie	1	$17
Creo Medical Inc.	1	$17
Ferring Pharmaceuticals Inc.	1	$16
E.r. Squibb & Sons, L.L.C.	1	$16
Kowa Pharmaceuticals America, Inc.	1	$15
Integra Lifesciences Corporation	1	$15
Sirtex Medical Inc	1	$15
Exelixis Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$476,713 in reported general payments places this provider in the 95th percentile of 108 colon & rectal surgery providers in Pennsylvania.

See all colon & rectal surgery providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$200,788

Medicare patients

370

Services billed

883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Doxycycline Hyclate	77	$301
Dicyclomine Hcl	14	$216

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Wynnewood

Henry SchoonyoungWynnewood$11K
Robert NooneWynnewood$3K
Bogdan ProtyniakWilkes-Barre$429K
James McCormickMonroeville$372K
Jeffrey ScowHershey$290K
Joshua BleierPhiladelphia$151K
Richard FortunatoPittsburgh$80K
Najjia MahmoudPhiladelphia$63K
Michael DeutschWest Reading$61K
Juan PoggioPhiladelphia$49K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →